Phase 2 evaluated the safety of the new FDCs as the primary objective. Participants received up to three times the standard dose of ivermectin in combination with 400 mg albendazole and, as expected, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback